Treatment of hypertension.
Treatment of heart failure (NYHA class II-IV) in patients receiving usual therapy eg, diuretics, digitalis and either ACE inhibitors or β-blockers but not both; presence of all these standard therapies is not mandatory.
In these patients, Tareg improves morbidity, primarily via reduction in hospitalization for heart failure. Tareg also slows the progression of heart failure, improves NYHA functional class, ejection fraction and signs and symptoms of heart failure, and improves quality of life vs placebo (see Pharmacology under Actions).
Post-Myocardial Infarction: To improve survival following myocardial infarction in clinically stable patients with signs, symptoms or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction.